2024-516386-36-00已完成2 期
A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 1
- 试验地点
- 2
- 主要终点
- Objective response rate is defined as the proportion of patients achieving either complete response or partial response according to the Lugano 2014 Classification for NHL as assessed by blinded independent central review (BICR)
研究概览
简要总结
To estimate the effectiveness of the module-defined study treatment by assessment of Objective Response Rate (ORR) based on Lugano 2014 Classification response criteria in each cohort as determined by Blinded Independent Central Review (BICR)
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Patient must be ≥ 18 years of age, at the time of signing the informed consent
- •ECOG performance status ≤ 2
- •Life expectancy > 6 months
- •Female patients must not be breast-feeding and must have a negative pregnancy test prior to start of dosing
- •Additional core inclusion criteria may apply, please refer to the protocol.
- •Additional Inclusion Criteria for Cohort 1A (R/R FL): Histologically confirmed diagnosis of FL Grade 1, 2, or 3a as assessed by investigator or local pathologist; Current need for systemic treatment based on the Investigator's opinion; Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after at least 2 prior systemic lines of therapy (including anti- CD20mAb and an alkylating agent). The treating physician should discuss with the patient all available treatment options, including the use of CAR-T cell therapy, evaluating benefits and risks before considering enrolment in this study; Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis
- •Additional Inclusion Criteria for Cohort 1B (R/R MZL): Histologically confirmed MZL including splenic, nodal, and extranodal subtypes as assessed by investigator or local pathologist; Current need for systemic treatment based on the Investigator's opinion; Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after at least 2 prior systemic lines of therapy (including at least one anti-CD20mAb directed regimen either as monotherapy or as chemoimmunotherapy; Helicobacter pylori eradication and radiation therapy alone will not be considered a systemic treatment regimen); Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis
- •Additional Inclusion Criteria for Cohort 1C (R/R MCL): Histologically confirmed MCL, with documentation of monoclonal B cells that have a chromosome translocation t(11;14)(q13;q32) and/or overexpress cyclin D1, as assessed by investigator or local pathologist; Relapsed, progressed or refractory (defined as failure to achieve at least a PR) after at least 2 prior systemic lines of therapy; Patients must have received as prior therapies: a) BTK inhibitor and b) Anti-CD20 monoclonal antibody therapy. The treating physician should discuss with the patient all available treatment options, including the use of CAR-T cell therapy, evaluating benefits and risks before considering enrolment in this study; Bi-dimensionally measurable disease on cross sectional imaging by CT or MRI with at least one nodal lesion > 1.5 cm in the long axis or at least one extranodal lesion > 1 cm in long axis.
排除标准
- •Prior malignancy (other than the disease under study), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which the patient has been disease free for ≥ 2 years
- •With the exception of alopecia, any unresolved non-haematological toxicities from prior therapy ≥ CTCAE Grade 2 at the time of starting study treatment
- •Known medically apparent CNS lymphoma or leptomeningeal disease
- •Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values at screening: a) Absolute neutrophil count < 1.0 × 10^9/L; < 0.75 × 10^9/L in participants with known bone marrow involvement of malignant disease b) Platelets < 75 × 10^9/L; < 50 × 10^9/L in participants with known bone marrow involvement of malignant disease c) Creatinine clearance < 50 mL/min per the Cockcroft and Gault formula
- •Clinically significant abnormalities of glucose metabolism as participants with diabetes mellitus type I or diabetes mellitus type II requiring insulin treatment OR Glycosylated haemoglobin ≥ 8.0% (63.9 mmol/mol)
- •Prior treatment with any of the following: a) Any investigational agents or study drugs from a previous clinical study within 5 half lives or 2 weeks from the first dose of capivasertib in this study b) Strong inhibitors or inducers of CYP3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or drugs that are sensitive to inhibition of CYP3A4 within 1 week prior to the first dose of study treatment. c) Prior allogenic HSCT within 6 months from the first dose of capivasertib (patients > 6 months after allogenic HSCT are eligible in the absence of active graft-versus-host disease and concomitant immune suppressive therapy). Prior cellular therapies (eg, CAR-T therapy) and/or autologous HSCT within 3 months from the first dose of capivasertib. d) Receipt of live, attenuated vaccine within 28 days before the first dose of study treatment(s). e) Patients who, due to other medical conditions /prior history /concomitant medications are, in the investigator's opinion, at a risk of a VTE and are not willing to accept the VTE prophylaxis, will be excluded. The initiation of an adequate VTE prophylaxis will be based on treating physician risk/benefit assessment and in agreement with the local management guidelines.
- •Additional exclusion core criteria may apply, please refer to the protocol
- •Module 1 specific exclusion criteria: Follicular lymphoma grade 3B; Known transformation to aggressive lymphoma, eg, large cell lymphoma; Patients who, in the Investigator's opinion, require immediate cytoreductive therapy for disease control
结局指标
主要结局
Objective response rate is defined as the proportion of patients achieving either complete response or partial response according to the Lugano 2014 Classification for NHL as assessed by blinded independent central review (BICR)
Objective response rate is defined as the proportion of patients achieving either complete response or partial response according to the Lugano 2014 Classification for NHL as assessed by blinded independent central review (BICR)
次要结局
- 1. Duration of response is defined as the time from the date of first documented response until date of documented progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause
- 2. Progression-free survival is defined as the time from the date of first dose until documented disease progression according to the Lugano 2014 Classification for NHL as assessed by BICR, or death due to any cause
- 3. Overall survival is defined as time from the date of first dose until the date of death due to any cause.
- 4. Patient-reported disease-related symptoms, functioning and health related quality of life as measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
- 5. Patient-reported symptomatic AEs and overall side effect burden as measured by PGI-TT and selected items from PRO CTCAE.
- 6. Time to first subsequent therapy or death (TFST) is defined as time from date of first dose until the start date of first subsequent anti-lymphoma therapy after discontinuation of study treatment or death due to any cause
- 7. Time to objective response (TTR) is defined as time from date of first dose until the date of first documented objective response per the Lugano 2014 Classification for NHL as assessed by BICR
- 8. Safety and tolerability will be evaluated in terms of AEs, vital signs, clinical laboratory and ECGs
- 9. Plasma concentration of capivasertib pre-dose and post-dose
研究者
Clinical Study Information Center
Scientific
AstraZeneca AB
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very longRelapsed or Refractory B-cell Non-Hodgkin LymphomaMedDRA version: 24.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000870-27-DKAstraZeneca AB272
进行中（未招募）
1 期
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very longRelapsed or Refractory B-cell Non-Hodgkin LymphomaMedDRA version: 20.0Level: PTClassification code: 10061275Term: Mantle cell lymphoma Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10076596Term: Marginal zone lymphoma Class: 100000004864MedDRA version: 24.0Level: LLTClassification code: 10067070Term: Follicular B-cell non-Hodgkin´s lymphoma Class: 10029104CTIS2024-516386-36-00AstraZeneca AB12
招募中
1 期
A phase 2 trial to study safety and efficacy of Capivasertib in patients with blood cancer where disease or cancer cell grows after a period of remission or response to treatment does not last very longRelapsed or Refractory B-cell Non-Hodgkin LymphomaMedDRA version: 24.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-000870-27-FRAstraZeneca AB272
进行中（未招募）
1 期
AZD4573 as Monotherapy or in Combination with Anti-cancer Agents in Patients with r/r PTCL or r/r cH- Relapsed/refractory Peripheral T-cell Lymphoma- Relapsed/refractory Classical Hodgkins LymphomaEUCTR2021-002570-54-FRAstraZeneca AB90
进行中（未招募）
1 期
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced CancerAdvanced Cancer Whose Tumours Contain Molecular AlterationsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2020-002529-27-FRAstraZeneca AB52